

# Local Coverage Determination (LCD): MoIDX: DecisionDx-Melanoma (L37750)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

## Contractor Information

CONTRACTOR NAME	CONTRACT TYPE	CONTRACT NUMBER	JURISDICTION	STATE(S)
Noridian Healthcare Solutions, LLC	A and B MAC	01111 - MAC A	J - E	California - Entire State
Noridian Healthcare Solutions, LLC	A and B MAC	01112 - MAC B	J - E	California - Northern
Noridian Healthcare Solutions, LLC	A and B MAC	01182 - MAC B	J - E	California - Southern
Noridian Healthcare Solutions, LLC	A and B MAC	01211 - MAC A	J - E	American Samoa Guam Hawaii Northern Mariana Islands
Noridian Healthcare Solutions, LLC	A and B MAC	01212 - MAC B	J - E	American Samoa Guam Hawaii Northern Mariana Islands
Noridian Healthcare Solutions, LLC	A and B MAC	01311 - MAC A	J - E	Nevada
Noridian Healthcare Solutions, LLC	A and B MAC	01312 - MAC B	J - E	Nevada
Noridian Healthcare Solutions, LLC	A and B MAC	01911 - MAC A	J - E	American Samoa California - Entire State Guam Hawaii Nevada Northern Mariana Islands

## LCD Information

### Document Information

LCD ID

Original Effective Date

L37750

For services performed on or after 02/10/2019

**LCD Title**

MoIDX: DecisionDx-Melanoma

**Revision Effective Date**

For services performed on or after 11/01/2019

**Proposed LCD in Comment Period**

N/A

**Revision Ending Date**

N/A

**Source Proposed LCD**

DL37750

**Retirement Date**

N/A

**AMA CPT / ADA CDT / AHA NUBC Copyright Statement**

CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

**Notice Period Start Date**

12/26/2018

**Notice Period End Date**

02/09/2019

Current Dental Terminology © 2019 American Dental Association. All rights reserved.

Copyright © 2019, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at [ub04@healthforum.com](mailto:ub04@healthforum.com).

**CMS National Coverage Policy**

Title XVIII of the Social Security Act, §1862(a)(1)(A). Allows coverage and payment for only those services that are

considered to be reasonable and necessary.

Title XVIII of the Social Security Act, §1833(e). Prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

42 Code of Federal Regulations (CFR) 410.32(a). Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.

CMS On-Line Manual, Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, §§80.0, 80.1.1, 80.2. Clinical Laboratory services.

CMS Internet-Only Manuals, Publication 100-04, Medicare Claims Processing Manual, Chapter 16, §50.5 Jurisdiction of Laboratory Claims, 60.12 Independent Laboratory Specimen Drawing, 60.2. Travel Allowance.

CMS Internet Online Manual Pub. 100-04 (Medicare Claims Processing Manual), Chapter 23 (Section 10) "Reporting ICD Diagnosis and Procedure Codes".

## **Coverage Guidance**

### **Coverage Indications, Limitations, and/or Medical Necessity**

The DecisionDx-Melanoma test is covered only when the following clinical conditions are met:

- Patients diagnosed with clinical stage, sentinel lymph node biopsy (SLNB) eligible, T1 and T2 cutaneous melanoma tumors (as defined in AJCC Staging Manual v8, 2017) with clinically negative sentinel node basins who are being considered for SLNB to determine eligibility for adjuvant therapy. (Per current NCCN and ASCO guidelines, SLNB eligible patients are defined as:
  - Patients with T1a tumors:
    - in whom there is significant uncertainty about the adequacy of microstaging (positive deep margin), or
    - with Breslow depth <0.8 mm and with other adverse features (e.g. very high mitotic index [ $\geq 2/\text{mm}^2$ ], lymphovascular invasion, or a combination of these factors)
  - Patients with T1b tumors ( $\geq 0.8$  mm or < 0.8 mm with ulceration)
- Patients with T2 tumors

Claims for DecisionDx-Melanoma testing will be denied when testing does not meet all of the above criteria.

## **Summary of Evidence**

### **Background**

Cutaneous melanoma (CM) is increasing in incidence in the U.S., with more than 87,000 cases expected to be diagnosed in 2017 and nearly 10,000 deaths each year [1]. Of these, more than 70,000 patients are diagnosed with Stage I or II disease (localized) as determined by the American Joint Committee on Cancer (AJCC) staging system [1]. Patients with early stage melanoma (i.e. AJCC Stage I-II) are regarded as good-prognosis based on population-based risk estimates. However, due to the greater number of individuals within these earlier stages, more than twice as many people diagnosed with early stage disease will ultimately die of melanoma compared to those diagnosed with Stage III melanoma [2].

The DecisionDx-Melanoma test is a 31-gene expression profile (GEP) that determines a CM patient's risk for metastatic disease [3-6]. The test classifies patients as having a tumor with low (Class 1) or high (Class 2) risk for developing metastasis within 5 years of diagnosis. Patients with a Class 1 tumor profile also have a low likelihood of being sentinel lymph node (SLN) positive. Thus, the individualized risk profile result of this test can be used to guide use of SLNB in the context of patient-specific management plans.

Per current national guidelines, a SLNB procedure is considered for all patients with melanoma pathologic Stage T1b and above, as well as those patients with T1a tumors in whom there is significant uncertainty about the adequacy of microstaging [7, 8]. Patients with a positive SLN are at substantially increased risk for distant metastatic disease and death [2], however, the procedure only provides prognostic information, and the MSLT-II study showed no survival benefit associated with completion lymphadenectomy in SLN positive patients [9]. Currently, the identification of SLN positive patients helps identify Stage III patients who can potentially benefit from targeted and immunotherapeutic agents in the adjuvant setting [10-13]. The procedure can be associated with complications in a substantial proportion of patients such as pain, seromas, nerve damage and edema, and requires a large team of dedicated personnel, including nuclear medicine physicians, surgeons, and pathologists [14-16]. It has been estimated that the cost of a SLNB can be 10 times that of a wide excision alone, and the cost per life saved in a patient population with low prevalence of positive SLN can approach 1 million dollars [17]. Overall, the likelihood of a positive SLN after the SLNB procedure is 16% [2, 18], but this is variable for specific populations [18-21]. Elderly patients account for a substantial proportion of CM patients, and 60% of melanoma-related deaths occur in patients ≥65 years-old. While older age is associated with a poor prognosis, fewer elderly patients are SLN positive [19-23], which indicates that the prognostic value of SLNB is limited in this population [24, 25].

In general, a 5% likelihood for a positive SLN is recommended as a threshold for performing this procedure in a patient population [18]. Analysis of Castle's retrospective cohort (n=782) identified that DecisionDx-Melanoma Class 1A patients (probability score <0.5) with tumors who had a Breslow thickness (BT) of ≤2.0 mm (AJCC T1-T2) achieved a positive SLNB rate below 5% [26]. To validate this clinical use of the Class 1A cut-point for the DecisionDx-Melanoma test, two contemporary, multi-center, prospective study cohorts were tested: 584 patient cohort from two published prospective studies (overall 14% SLN positive rate) [6, 27] and a 837 patient cohort from prospectively tested patients at 5 large academic institutions (overall 12% SLN positive rate) [26]. The rate of SLN positivity in both prospective study cohorts aligns with the SLN positivity rate in the general population of melanoma patients who have undergone SLNB. The results show that in patients from the Medicare-eligible population (65 years old and over) who had a SLNB performed, those patients who had a DecisionDx-Melanoma Class 1A T1 or T2 tumor, have a 98.4% probability of being SLN negative. Thus, in this patient group, the DecisionDx-Melanoma test achieves a NPV that is comparable to other molecular tests used to guide surgical management decisions [28-31].

Analysis of the two prospective cohorts combined (n=1,421 patients) shows that SLN positivity rates are enriched from 12.8% using current SLNB criteria to 18.6% in those patients who would undergo the SLN biopsy procedure (T1/T2 with a Class 2 DecisionDx-Melanoma test result and T3/T4 patients). The rate of SLN positivity in the 65 years and older population from Castle's prospective cohort (n=629) is 14.6% of Class 1A patients and 11.9% for Class 2B patients. SLNB positivity rates for T3 tumors is 8.7% for Class 1A compared to 18% for Class 1B-2B; for T4 tumors it is 17% and 17% respectively. Importantly, the 5-year melanoma specific survival (MSS) rate for T1/T2 Class 1 patients remains favorable; with 99% MSS, comparable to that observed in T1a tumors and for which current guidelines do not recommend SLNB [7, 32, 33]. Furthermore, T1/T2 Class 1 patients show 5-year overall survival (OS) of 97% and distant metastasis free survival (DMFS) of 93% [33]. The MSLT-II study demonstrated that a delay in lymph node dissection does not adversely affect survival, thus clinical follow up of Class 1 patients and lymphadenectomy for those few who develop clinically detectable nodal disease should achieve similar outcomes to those who currently undergo a planned SLNB [9]. Thus, the test identifies a patient population with <5% likelihood of a positive SLN and high survival rates and therefore has utility in guiding SLNB decisions in patients 65 years-old and over with T1-T2 CM tumors. In this population, the test could potentially reduce the rate of SLNB by up to 78% while still maintaining a MSS survival rate of 99% in those patients with low-risk tumor biology who can safely avoid the procedure.

Clinical validation of DecisionDx-Melanoma as a prognostic test for CM patients was performed in three multicenter, prospectively designed archival tissue studies including 782 patients [3-5]. These studies have shown that the test accurately predicts risk for local/regional recurrence, distant metastasis, melanoma-related mortality, and all-cause mortality independent of clinicopathologic factors used in staging and that the test shows improved sensitivity and negative predictive value (NPV) for recurrence-free (RFS), distant metastasis-free (DMFS), melanoma-specific (MSS) and overall (OS) survival individually or in conjunction with established clinicopathologic factors. Three prospective, independent studies (n= 510) and an interim analysis of two prospective registries (n=322) have confirmed the prognostic accuracy of DecisionDx-Melanoma [6, 34-36].

The DecisionDx-Melanoma test may improve net health outcomes by accurately identifying patients who are at risk of developing metastatic disease and would otherwise go undetected, as well as patients with a low likelihood of having a positive SLN. Net health outcomes are improved for low risk Class 1 patients who can consider avoiding SLNB and associated surgical and anesthesia risk (T1-T2 patients), as well as intensive follow up and exposure to radiation from imaging procedures, and for high risk Class 2 patients by improved guidance to perform SLNB.

## Summary of Analytical and Clinical Performance

### General

Intended Use	The DecisionDx-Melanoma test is intended for SLNB-eligible T1 and T2 cutaneous melanoma (as defined in AJCC Staging Manual v8, 2017) with clinically negative sentinel node biopsy. SLNB being considered for SLNB to determine eligibility for adjuvant therapy
Validated Specimen Type(s)	Formalin-fixed, paraffin-embedded (FFPE) specimens of the primary tumor.

### Analytical Performance [37]

Description	Results (with 95% Confidence Intervals if applicable) <sup>1</sup>
Repeatability (within run precision) 21 samples (in triplicate) three PCR cards, 1 instrument, 1 operator, 3 runs 2 days, 1 manufacturing reagent lot.	Binary Classification (Class 1 / Class 2): 100% (94-100%) Subclassification (Class 1A/1B; Class 2A/2B): 98% (91-100%)
Intermediate precision (between run precision)	
<b>Inter-operator/instrument:</b> 22 samples, 2 instruments, 2 operators, 2 runs, 2 day, 1 manufacturing reagent lots	Binary Classification (Class 1 / Class 2): 95% (77-100.0%) Subclassification (Class 1A/1B; Class 2A/2B): 95% (77-100%)
<b>Inter-assay:</b> 143 samples, 2 instruments, 2 operators, 15 runs, multiple days (2.5 year interval), multiple manufacturing lots	Binary Classification (Class 1 / Class 2): 99% (96-100.0%) Subclassification (Class 1A/1B; Class 2A/2B): 92% (87-96%)
Reproducibility (between sites)	Not applicable
Minimum input RNA quantity	5 ng RNA
Minimum tumor content (for FFPE specimens)	40% by histomorphology
Limit of blank (LOB)	CT undetermined for blank
Limit of detection (LOD)	Not applicable
Limits of quantitation (LOQ)	Not applicable
Linearity	Not applicable
Interfering substances	Not applicable <sup>2</sup>
Specimen stability, primary	FFPE x 4 years at RT per literature and up to 16 years in outcom

Specimen stability, intermediate (extracted RNA)	analysis from validation cohort 96 hours when stored at -80°C per SOP
Specimen stability, intermediate (cDNA)	96 hours when stored at 4°C per SOP 30 days when stored at -20°C per SOP Applied Biosystems TaqMan® Low Density Array, -20°C x 24 months (lab) Applied Biosystems TaqMan® Open Array, -20°C x 12 months (lab) Applied Biosystems High-Capacity cDNA Reverse Transcription Kit, -20 °C x 8 months / 3 months (lab)  Applied Biosystems TaqMan® PreAmp Master Mix Kit, 4°C x 9 months (lab)
Critical reagent closed/shelf-life stability (manufacturer's recommendations/lab validated)	Applied Biosystems TaqMan® OpenArray Master Mix, -20°C x 12 months (lab)  Applied Biosystems RNase Inhibitor, -20 °C x 42 months / 3 months (lab) Qiagen Deparaffinization Solution, room temperature x 3 months (lab) Qiagen RNeasy Lysis Buffer PKD, room temperature x 3 months (lab)  Qiagen Dnase Booster Buffer, room temperature x 3 months (lab) Qiagen RNeasy Lysis Buffer K, room temperature x 3 months (lab)  Qiagen QIAasympyphony RNA kit, room temperature x 3 months (lab)
Critical reagent open/in use stability	Per lab validation or manufacturer's specifications

<sup>1</sup>Using Clopper-Pearson method

<sup>2</sup>Since the gene expression profile is based on ratios of gene to controls, rather than an absolute value, the effect of an interfering agent is expected to affect all genes equally and result in failed amplification.

### Clinical Performance: Utility

Data below shows that using the DecisionDx-Melanoma test for SLNB guidance in T1/T2 as defined by AJCC v8 identifies a patient population with <5% likelihood of a positive SLN with high rates of MSS, OS and DMFS, OS and therefore may have utility in guiding SLNB decisions in Medicare patients. In this population, the test will reduce the rate of SLNB by up to 52% while still maintaining a MSS survival rate of 99% in those patients with low-risk tumor biology who can safely avoid the procedure.

### Summary of DecisionDx-Melanoma performance in SLNB guidance in T1/T2 melanoma patients ≥65 years old, eligible for SLNB biopsy

Cohort	Overall N	NPV	SLN+ Rate T1/T2 Patients	SLN+ Rate T1/T2 Class 1B-2B Patients	SLN+ Rate All Patients Directed to SLNB
Castle Prospective Studies <sup>c</sup>	193	0.99 (0.93-1)	3.33%	7.32%	15.79%
Independent Validation Cohort <sup>d</sup>	335	0.97 (0.93-0.99)	5.29%	10.00%	12.23%
Combined	528	0.98 (0.95-0.99)	4.61%	9.09%	13.58%

NPV = Negative Predictive Value in for SLN positivity in SLNB eligible T1/T2 patients with Class 1A DecisionDx-Melanoma test result

<sup>a</sup>Patients eligible for SLNB per NCCN guidelines or had a SLNB procedure performed

<sup>b</sup>SLNB positive rate in all patients undergoing SLNB after guidance with test (T1/T2 Class 1B-2B and T3/T4)

<sup>c</sup>Data from two contemporary, prospective, multicenter studies (total n=584) [6, 27]

<sup>d</sup>Data from independent cohort from 5 academic centers (total n=837) [26]

**Expected survival outcomes in T1/T2 patients who avoid or undergo SLNB based on DecisionDx-Melanoma class result**

Patient Group	MSS	OS	DMFS
T1/T2 Class 1 (No SLNB)	99.3%	97.2%	93.4%
T1/T2 Class 2 SLNB Negative	95.3%	95.3%	86.3%
T1/T2 Class 2 SLNB Positive	73.8%	52.4%	52.5%

Data from three retrospective, multicenter cohorts (N=690)

Median follow up time of cohort = 6.5 yr [3-5, 26]

Note: Limited data for Class 1 T1/T2 patients who were found to be SLNB positive under current guidelines showed MSS, OS and DMFS rates of 100%, 90.7 and 75.7%.

**Clinical Performance: Validity**

**Summary of event rates in DecisionDx-Melanoma clinical validity studies**

Study	Design	Population	Non-censored recurrence rate (95% CI)		Non-censored (95% CI)
			Class 1	Class 2	
Gerami et al., 2015 CCRa [3]	Archival, prospective design	Stage I-II, n=78; mf/u: 5.7 years	5.8% (1.2-16%) 3/52	69% (48-86%) 18/26	3.8% (0.4-10.2%) 2/52
Gerami et al., 2015 JAADB [4]	Archival, prospective design	SLN-eligible, Stage I-III, n=217; mf/u: 4.2 years	21% (13-32%) 16/76	65% (56-72%) 91/141	18% (10-27%) 14/77
Zager et al., 2017 [5]	Archival, prospective design	Stage I-III, n=523; mf/u: 6.1 years	13% (9.8-18%) 42/314	48% (41-55%) 100/209	9% (6-12%) 28/314
Greenhaw et al., 2017 [34]	Consecutively tested, single center	Stage I-II, n=256; mean f/u: 1.9 years	1.4% (0.3-4%) 3/214	24% (12-39%) 10/42	
Hsueh et al., 2017 [35]	Prospective, single center	Stage I-III, n=159; mf/u: 2.1 years	2.6% (0.53-7.3%) 3/117	45% (30-61%) 19/42	
Hsueh et al., 2017 [6]	Prospective registries	Stage I-III, n=322; mf/u: 1.5 years	2% (0.66-4.6%) 5/248	27% (17-38%) 20/74	1% (0.1-2.2%) 2/248
Renzetti et al., 2017 [36]	Consecutively tested, single center	Stage I-III, n=95; mf/u: 0.9 years	4.9% (0.6-17%) 2/41	24.1% (13-38%) 13/54	2.4% (0.06-7.1%) 1/41

mf/u = median follow-up

Confidence intervals calculated by the Coppler-Pearson method

<sup>a</sup>Recurrence in Gerami et al., 2015 CCR included sentinel lymph node positivity as an event, while all other studies did not. Therefore, for this study, only Stage I-II patients are included.

<sup>b</sup>Patients in this study were eligible for SLNB so they include Stage I-II patients at a higher risk of metastasis, thus event rates in Class 1 is expected to be higher than in other studies.

**Summary of survival outcomes in DecisionDX-Melanoma clinical validity studies**

Study	Design	Population	Recurrence-free Survival (RFS) rate (95% CI)	
			Class 1	Class 2
Gerami et al., 2015 CCRa [3]	Archival, prospective design	Stage I-II, n=78; mf/u: 5.7 years	98% (93-100%) <sup>c</sup>	37% (21-56%)

Gerami et al., 2015 JAADb[4]	Archival, prospective design	SLN-eligible, Stage I-III, n=217; mf/u: 4.2 years	79% (70-90%) <sup>c</sup>	33% (26-43%)
Zager et al., 2017 [5]	Archival, prospective design	Stage I-III, n=523 mf/u: 6.1 years	88% (85-92%) <sup>c</sup>	52% (46-60%)
Greenhaw et al., 2017 [34]	Consecutively tested, single center	Stage I-II, n=256; mean f/u: 1.9 years	98% (95-100%) <sup>d</sup>	74% (59-93%)
Hsueh et al., 2017 [35]	Prospective, single center	Stage I-III, n=159 mf/u: 2.1 years	97% (95-100%) <sup>e</sup>	54% (41-72%)
Hsueh et al., 2017 [6]	Prospective registries	Stage I-III, n=322 mf/u: 1.5 years	97% (95-100%) <sup>f</sup>	77% (67-88%)

mf/u = median follow-up

Survival rates and confidence intervals calculated by Kaplan-Meier method

<sup>a</sup>Recurrence in Gerami et al., 2015 CCR included sentinel lymph node positivity as an event, while all other studies did not. Therefore, for this study, only Stage I-II patients are included.

<sup>b</sup>Patients in this study were eligible for SLNB so they include Stage I-II patients at a higher risk of metastasis, thus event rates in Class 1 is expected to be higher than in other studies

<sup>c</sup>5-year survival outcomes

<sup>d</sup>3-year survival outcomes

<sup>e</sup>2-year survival outcomes

<sup>f</sup>1.5-year survival outcomes

## Analysis of Evidence (Rationale for Determination)

### Level of Evidence

Quality of evidence – Moderate

Strength of evidence – Low

Weight of evidence - Low

This contractor will cover the DecisionDx-Melanoma test for patients diagnosed with SLNB eligible T1b and T2 tumor who are being considered for SLNB. The DecisionDx-Melanoma assay should not be ordered if a patient and his/her physician do not intend to act upon the test result. Continued coverage is dependent on the publication and/or presentation of additional clinical utility data demonstrating the impact of the test's use on patient management decisions with (1) 95% or greater DMFS and MSS at 3 years in patients directed to no SLNB by the test compared to standard of care, and (2) evidence of higher SLNB positivity in patients selected for this procedure by the test compared to standard of care.

---

## General Information



## Associated Information

N/A

## Sources of Information

N/A

## Bibliography

1. Siegel, R.L., K.D. Miller, and A. Jemal, *Cancer Statistics, 2017*. CA Cancer J Clin, 2017. **67**(1): p. 7-30.
2. Morton, D.L., et al., *Final trial report of sentinel-node biopsy versus nodal observation in melanoma*. N Engl J Med, 2014. **370**(7): p. 599-609.
3. Gerami, P., et al., *Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma*. Clin Cancer Res, 2015. **21**(1): p. 175-83.
4. Gerami, P., et al., *Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy*. J Am Acad Dermatol, 2015. **72**(5): p. 780-5 e3.
5. Zager, J.S., et al., *Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients*. BMC Cancer, 2018. **18**(1): p. 130.
6. Hsueh, E.C., et al., *Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test*. J Hematol Oncol, 2017. **10**(1): p. 152.
7. Coit, D.G., et al., *Melanoma, Version 2.2018*. NCCN Clinical Practice Guidelines in Oncology 2018.
8. Wong, S.L., et al., *Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update*. J Clin Oncol, 2017: p. JCO2017757724.
9. Faries, M.B., et al., *Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma*. N Engl J Med, 2017. **376**(23): p. 2211-2222.
10. Eggermont, A.M., et al., *Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial*. Lancet Oncol, 2015. **16**(5): p. 522-30.
11. Eggermont, A.M., et al., *Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy*. N Engl J Med, 2016. **375**(19): p. 1845-55.
12. Long, G.V., et al., *Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma*. New England Journal of Medicine, 2017. **0**(0): p. null.
13. Weber, J., et al., *Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma*. New England Journal of Medicine, 2017. **0**(0): p. null.
14. Moody, J.A., et al., *Complications of sentinel lymph node biopsy for melanoma - A systematic review of the literature*. Eur J Surg Oncol, 2017. **43**(2): p. 270-277.
15. Ascha, M., M.S. Ascha, and B. Gastman, *Identification of Risk Factors in Lymphatic Surgeries for Melanoma: A National Surgical Quality Improvement Program Review*. Ann Plast Surg, 2017.
16. Bagaria, S.P., M.B. Faries, and D.L. Morton, *Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute*. J Surg Oncol, 2010. **101**(8): p. 669-76.
17. Agnese, D.M., et al., *Cost-effectiveness of sentinel lymph node biopsy in thin melanomas*. Surgery, 2003. **134**(4): p. 542-7; discussion 547-8.
18. Han, D., et al., *Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma*. J Clin Oncol, 2013. **31**(35): p. 4387-93.
19. Cavanaugh-Hussey, M.W., et al., *Older Age is Associated with a Higher Incidence of Melanoma Death but a Lower Incidence of Sentinel Lymph Node Metastasis in the SEER Databases (2003-2011)*. Ann Surg Oncol, 2015. **22**(7): p. 2120-6.
20. Sinnamon, A.J., et al., *Association Between Patient Age and Lymph Node Positivity in Thin Melanoma*. JAMA Dermatol, 2017.
21. Sondak, V.K., et al., *Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model*. Ann Surg Oncol, 2004. **11**(3): p. 247-58.
22. Balch, C.M., et al., *Age as a prognostic factor in patients with localized melanoma and regional metastases*. Ann Surg Oncol, 2013. **20**(12): p. 3961-8.

23. Balch, C.M., et al., *Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients*. *Ann Surg Oncol*, 2014. **21**(4): p. 1075-81.
24. Fleming, N.H., et al., *Impact of age on the management of primary melanoma patients*. *Oncology*, 2013. **85** (3): p. 173-81.
25. Macdonald, J.B., et al., *Malignant melanoma in the elderly: different regional disease and poorer prognosis*. *J Cancer*, 2011. **2**: p. 538-43.
26. Cook RW, Johnson C, Monzon FA. Determination of sentinel lymph node biopsy eligibility using a 31-gene expression profile test in melanoma patients. Presented at in *American College of Mohs Surgery Meeting 2018*. Chicago, IL. (<http://castlebiosciences.com/wp-content/uploads/2018/05/Cook-ACMS-2018-SLNB-poster.pdf>)
27. Dillon, L.D., et al., *Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients*. *SKIN J Cutaneous Med*, 2018. **2**(2): p. 111-121.
28. *Local Coverage Determination (LCD): MoIDX-CDD: ConfirmMDx Epigenetic Molecular Assay (L35632)*. 2017, Palmetto GBA.
29. Labourier, E., et al., *Multi-categorical testing for miRNA, mRNA and DNA on fine needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology*, in *ENDO 2015: 97th Meeting and Expo of the Endocrine Society 2015*.
30. Silvestri, G.A., et al., *A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer*. *New England Journal of Medicine*, 2015. **373**(3): p. 243-251.
31. *Local Coverage Determination (LCD): MoIDX: Percepta© Bronchial Genomic Classifier (L36854)*. 2017, Palmetto GBA.
32. Gershenwald, J.E., et al., *Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual*. *CA Cancer J Clin*, 2017. **67**(6): p. 472-492.
33. Cook, R.W., K.R. Covington, and F.A. Monzon, *Continued evaluation of a 31-gene expression profile to predict metastasis in an expanded cohort of 782 cutaneous melanoma patients*, in *23rd International Pigment Cell Conference (IPCC) 2017*: Denver, CO.
34. Greenhaw, B., D. Brodland, and J. Zitelli, *Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test*. *Dermatol Surg*, 2018. **In Press**.
35. Hsueh, E., et al., *Prospective validation of gene expression profiling in primary cutaneous melanoma*. *J Clin Oncol*, 2016. **34**(suppl; abstr 9565).
36. Renzetti, M., et al., *Combined experience of two tertiary referral centers with DecisionDx-Melanoma GEP testing*, in *Society of Surgical Oncology 2017*: Seattle, WA. 37. Cook, R.W., et al., *Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients*. *Diagn Pathol*, 2018. **13**(1): p. 13.
37. Cook, R.W., et al., *Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients*. *Diagn Pathol*, 2018. **13**(1): p. 13.

## Revision History Information

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION	REASON(S) FOR CHANGE
11/01/2019	R2	<p>The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to</p>	<ul style="list-style-type: none"> <li>• Other (The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.)</li> </ul>

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION	REASON(S) FOR CHANGE
		the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.	
11/01/2019	R1	<p>As required by CR 10901, all billing and coding information has been moved to the companion article, this article is linked to the LCD.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</p>	<ul style="list-style-type: none"> <li>• Revisions Due To Code Removal</li> </ul>

## Associated Documents

### Attachments

N/A

### Related Local Coverage Documents

Article(s)

A57417 - Billing and Coding: MoIDX: DecisionDx-Melanoma

A56230 - Response to Comments: MoIDX: DecisionDx-Melanoma

LCD(s)

DL37750

- (MCD Archive Site)

### Related National Coverage Documents

N/A

### Public Version(s)

Updated on 01/29/2020 with effective dates 11/01/2019 - N/A

Updated on 10/08/2019 with effective dates 11/01/2019 - N/A

Updated on 12/14/2018 with effective dates 02/10/2019 - N/A

## Keywords

N/A